By Stephen Levin
US device companies have long debated the pros and cons of various strategies for commercializing their products in Europe, all...
Invatec: Translating Global Success in Vascular Devices to the US Market
Invatec has grown to be the leading native European interventional vascular device company and has now set its sights on the US market. By focusing first on peripherals and following with drug-eluting balloons, not stents, Invatec is looking to compete against the major device companies on their home turf.
More from Global Vision
• By
The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.
• By
China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.
• By
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
• By
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
More from In Vivo
The biotech's C1q inhibitor, vonaprument, preserved vision but missed the primary Phase II endpoint on lesion growth. The stakes are high for a Phase III with a different primary endpoint.
An interactive look at pharma, medtech and diagnostics deals made during August 2025. Data courtesy of Biomedtracker.
• By
The mathematician-turned-CEO is building an atlas of clinical immune biology to revolutionize precision medicine.